

Immunization Safety Surveillance

Guidelines for immunization programme managers
on surveillance of adverse events following immunization

Third Edition



Immunization Safety Surveillance

Guidelines for immunization programme managers
on surveillance of adverse events following immunization

Third Edition

WHO Library Cataloguing in Publication Data

Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization. Third edition.

1. Immunization. 2. Immunization programs – organization and administration. 3. Safety management – standards. I. World Health Organization Regional Office for the Western Pacific.

ISBN 978 92 9061 745 7 (NLM Classification: WA 115)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications—whether for sale or for non-commercial distribution—should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html). For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines (fax: +632 521 1036, email: publicationsWPRO@wpro.who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Photographs: ©WHO

Contents

Preface	vii
Glossary	viii
Abbreviations	xi
Purpose	1
<hr/>	
Principles of immunization and vaccine	3
Immunity.....	3
Vaccine.....	4
Classification of vaccines.....	5
Other components in vaccines (excipients).....	6
Contraindication and precaution.....	7
<hr/>	
Adverse events following immunization (AEFIs)	9
Vaccine reactions.....	10
Immunization error–related reactions.....	17
Immunization anxiety-related reactions.....	20
Coincidental events.....	21
<hr/>	
Establishing an immunization safety surveillance system	25
Objectives.....	25
Steps for establishing a system.....	26
Roles and responsibilities of National Regulatory Authorities in immunization safety surveillance.....	27
Roles and responsibilities of immunization programmes in immunization safety surveillance.....	28
Private sector.....	33
National immunization safety expert committee.....	34
Differences between surveillance of AEFIs and of adverse drug reactions.....	35
Evaluation of the immunization safety surveillance system.....	36
<hr/>	
Reporting AEFIs	39
Which events should be reported?.....	39
When to report?.....	41
How to report?.....	41
Reporting AEFIs during immunization campaigns.....	42
Barriers to reporting.....	43
Private sector reporting.....	43
Vaccine Adverse Events Information Management System (VAEIMS).....	43

Investigating AEFIs	45
Why should AEFI reports be investigated?	45
Which AEFI reports should be investigated?	45
Who should investigate AEFI?	46
When to investigate AEFI	46
How to investigate AEFI	46
Laboratory testing: vaccine	48
Laboratory testing: human specimens	48
Investigating AEFI clusters	50
Investigation of deaths	51
Analysis of AEFI data	53
Who should analyse the data?	53
Purpose of analysis at different levels	53
How should the data be analysed and interpreted?	55
How should a cause be determined?	58
Causality assessment of an AEFI	59
Levels of AEFI causality assessment	59
Scientific basis: the criteria for causality	60
Case selection for AEFI causality assessment	61
Prerequisites for AEFI causality assessment	61
Causality assessment: method	61
Actions and follow-up to AEFIs	65
Patient care	65
Actions following investigation and causality assessment	65
Logistics	65
Strengthening cold chain	66
Injection safety	66
Training opportunities for vaccine safety	67
Vaccine safety basic training	67
Vaccine safety advance training	68
E-learning course on vaccine safety basics	68
Communication	69
Communication with parents and community	69
Communication with health staff	70
Communicating with stakeholders	70
Communicating with the media	70
Advance preparation	70
Crisis management	71
Vaccine hesitancy	72
Regional guide on vaccine safety communication	73

Bibliography	74
---------------------	-----------

Websites on vaccine and immunization safety	76
--	-----------

Annexes	78
----------------	-----------

Annex A: Risks of vaccine-preventable diseases (VPD).....	78
Annex B: AEFI case definitions and treatment	84
Annex C: Recognition and treatment of anaphylaxis.....	87
Annex D: Checklist for monitoring of immunization safety surveillance systems.....	92
Annex E: Reporting form for AEFI.....	93
Annex F: Detailed core variables for required reporting in AEFI surveillance.....	95
Annex G: AEFI case investigation form.....	96
Annex H: AEFI line listing.....	102
Annex I: AEFI causality assessment checklist.....	103

List of tables and figures

Tables

Table 1:	Types of vaccine.....	5
Table 2:	Cause-specific categorization of AEFIs (CIOMS/WHO 2012).....	9
Table 3:	Frequency of vaccine adverse reactions (VAR).....	11
Table 4:	Immunization error-related reactions.....	17
Table 5:	Estimated coincidental infant deaths temporally linked to DPT/PvV immunization in selected countries in the Western Pacific Region.....	22
Table 6:	Regulatory control functions of country NRA by vaccine source.....	27
Table 7:	Responsibilities by programme implementation level.....	31
Table 8:	List of reportable AEFIs.....	40
Table 9:	Core variables with minimum information required for reporting in AEFI surveillance.....	41
Table 10:	Laboratory testing to investigate AEFIs by working hypothesis.....	49
Table 11:	Guide to specimen samples obtained following selected AEFIs.....	49
Table 12:	Cause-specific cluster characteristics.....	51
Table 13:	Actions to safeguard the public during an investigation.....	52
Table 14:	Purpose of analysis at different levels.....	54
Table 15:	Options for selecting a denominator.....	55
Table 16:	Factors to consider when comparing rates of AEFIs.....	57
Table 17:	Actions to be taken upon completion of the investigation/ causality assessment.....	66
Table 18:	Media plan.....	71

Figures

Figure 1:	Steps in an AEFI investigation.....	47
Figure 2:	Identifying cause of AEFI cluster.....	50
Figure 3:	Vaccine reaction rate, observed rate and background rate.....	56
Figure 4:	Causality assessment: eligibility.....	62
Figure 5:	Causality assessment: algorithm.....	63

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27139

